Jazz Pharmaceuticals plc is a dynamic specialty biopharmaceutical company that identifies, develops and commercializes innovative products to address unmet medical needs in focused therapeutic areas, always keeping in mind our mission to improve patients’ lives. Our unwavering commitment to advancing patient care is demonstrated every day. Living our core values of integrity, passion, collaboration, innovation and the pursuit of excellence is the key to our success. Headquartered in Dublin, Ireland with locations in California and Pennsylvania, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals. Jazz Pharmaceuticals markets a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.
Webcast ImageWebcast
Q2 2014 Jazz Pharmaceuticals Earnings Conference Call (Live)
08/05/14 at 4:30 p.m. ET
Press Releases
Jul 22 2014 - 4:05 p.m.
Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014
Jul 21 2014 - 4:53 p.m.
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386
Jul 02 2014 - 8:00 a.m.
Jazz Pharmaceuticals Announces Agreement To Acquire Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc.


Sign up to receive e-mail alerts whenever Jazz Pharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.